Beijing, Shanghai, Boston, December 7, 2023 — Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, is pleased to announce today that the company will present its clinical results in the oral abstract session at 2024 ASCO Gastrointestinal Cancers Symposium (2024 ASCO GI). The presentation details are as follows:
Abstract ID: 604
Abstract Title: Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors
Presentation Time: Jan 19, 2024 2:10 PM - 2:20 PM (San Francisco Time)
Jacobio continues to explore the application of glecirasib in pancreatic cancer. Glecirasib’s registrational pivotal study for pancreatic cancer was approved by CDE in July 2023, which became the first global pancreatic cancer KRAS G12C registrational clinical study. The study results will be used to submit NDA (New Drug Application) for pancreatic cancer.
In August 2023, based on the clinical efficacy and safety data from ongoing clinical trials, glecirasib was granted breakthrough therapy designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the pancreatic cancer patients with a KRAS G12C mutation who have progressed after frontline standard care treatment. Pancreatic cancer is a malignant tumor and there is a lack of effective treatment currently. The five-year overall survival rate is only 5%. The BTD will expedite the clinical development of glecirasib and accelerate its early access to the patients.
2024 ASCO GI will be held in San Francisco, US, from January 18 to January 20. For more information, please visit the official website of the ASCO GI: https://conferences.asco.org/gi/program
Glecirasib is a KRAS G12C inhibitor developed by Jacobio. A number of Phase I/II clinical trials of glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. This includes a pivotal clinical trial in NSCLC in China; a monotherapy study for STK11 co-mutated NSCLC in the front-line setting, combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with Cetuximab in colorectal cancer, and a registrational pivotal clinical trial in pancreatic cancer.
Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people's health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.